CEO Henderson sells 20,000 shares ($1.6M) via pre-arranged 10b5-1 plan at APGE; stock down 9.2% in 30 days.
Michael Thomas Henderson, CEO of Apogee Therapeutics, executed 2 separate sales totaling 20,000 shares for $1,641,710.73 on 2026-05-13 at an average price of $82.09 per share. This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2025-08-13, meaning it was scheduled in advance rather than a discretionary decision. The sale reduced his holdings from 1.14M to 1.12M shares—a modest reduction relative to his total position. The company is unprofitable with net income of $-74,111,000.00, and the stock is currently trading at $81.14, down 9.2% over the past 30 days and down 14.9% from its 52-week high of $95.32. Since this trade is scheduled under a 10b5-1 plan, it does not reflect a timing decision by the CEO; rather, it represents a pre-planned reduction in holdings that occurred while the company operates at a loss and equity is under recent downward pressure.